Лучшие больницы для «Liver Cirrhosis Treatment» в Ченнаи, Индия

Liver cirrhosis represents the end-stage histological consequence of sustained hepatic injury — most commonly from chronic hepatitis B or C virus infection, non-alcoholic steatohepatitis (NASH/MASLD), alcohol-related liver disease, autoimmune hepatitis, or cholestatic disorders such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). At the cellular level, repeated cycles of hepatocyte necrosis and inflammatory repair drive portal fibroblast and hepatic stellate cell activation, culminating in fibrous septa that distort the hepatic sinusoidal architecture, elevate intrahepatic vascular resistance, and progressively replace functional parenchyma. The net result is a dual failure of synthetic function (coagulopathy, hypoalbuminaemia, hyperbilirubinaemia) and portal hypertensive sequelae (oesophageal/gastric varices, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and hepatorenal syndrome).

• ELIGIBLE PATIENTS — MEDICAL MANAGEMENT & HEPATOLOGY CARE:
• Compensated cirrhosis (Child-Pugh A/B; MELD <15) with identifiable and treatable aetiology (viral hepatitis, NASH, autoimmune, cholestatic)
• Patients with portal hypertension complications (varices, mild-moderate ascites) requiring endoscopic or interventional management (EVL, TIPS evaluation)
• Patients on active hepatitis B/C antiviral therapy requiring specialist monitoring and dose optimisation
• NASH/MASLD-associated cirrhosis with concurrent metabolic syndrome requiring integrated hepatology-endocrinology co-management
• +29 more

TIER 1 — Cause-specific Disease-modifying PHARMACOTHERAPY:

The foundation of cirrhosis management is elimination or suppression of the underlying injury. For HCV-related cirrhosis, 12–24 week regimens of NS5A/NS5B inhibitor-based direct-acting antivirals (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, ledipasvir/sofosbuvir) achieve >95% sustained virological response (SVR12), halting fibrosis progression and — in compensated cirrhosis — enabling partial histological regression. For HBV, indefinite nucleos(t)ide analogue therapy (tenofovir alafenamide [TAF] or entecavir) suppresses viral replication to undetectable levels, significantly reducing decompensation and HCC risk. For PBC, ursodeoxycholic acid (UDCA 13–15 mg/kg/day) remains first-line; obeticholic acid (OCA) is added in UDCA non-responders. Autoimmune hepatitis is managed with prednisolone plus azathioprine induction followed by azathioprine maintenance. NASH/MASLD-related cirrhosis currently lacks an approved antifibrotic, but GLP-1 receptor agonists (semaglutide), SGLT-2 inhibitors, and pioglitazone show meaningful benefit in clinical trials and are used off-label in select cases.

TIER 2 — Portal Hypertension & Complication MANAGEMENT:

• Non-selective beta-blockers (NSBB): Carvedilol (preferred; 6.25–12.5 mg/day) or propranolol for primary/secondary prophylaxis of variceal bleeding. Superior haemodynamic response (HVPG reduction ≥20% or to <12 mmHg) correlates with reduced decompensation events.
• Endoscopic Variceal Ligation (EVL): Band ligation every 2–4 weeks until variceal eradication; combined with NSBB for secondary prophylaxis.
• Endoscopic injection sclerotherapy: Reserved for acute bleeding when EVL technically not feasible.
• Balloon tamponade / Sengstaken-Blakemore tube: Bridge to definitive haemostasis in refractory acute variceal haemorrhage.
• Transjugular Intrahepatic Portosystemic Shunt (TIPS): A 10–12 mm PTFE-covered stent placed fluoroscopically between hepatic vein and portal vein to decompress the portal system. Indicated for refractory ascites, recurrent variceal bleeding, Budd-Chiari syndrome. TIPS significantly reduces re-bleeding and ascites-related hospitalisations; covered stents (Viatorr) maintain patency >80% at 2 years.
• Paracentesis ± intravenous albumin (8 g/L drained): Large-volume paracentesis (LVP) with albumin replacement for refractory tense ascites.
• Terlipressin + albumin: First-line pharmacotherapy for hepatorenal syndrome type 1 (HRS-AKI); terlipressin 1–2 mg IV every 4–6 hours with 1 g/kg albumin bolus achieves HRS reversal in ~35–40% of patients.
• Rifaximin 550 mg BD + lactulose: Standard regimen for secondary prevention of overt hepatic encephalopathy.

PHASE 1 — Remote Pre-consultation (WEEKS 1–2):

The patient submits existing records (ultrasound/CT/MRI liver, viral serology, MELD score, endoscopy reports, current medications) to GAF Healthcare. A multidisciplinary team — hepatologist, transplant surgeon, interventional radiologist — reviews the file and issues a preliminary management plan within 48–72 hours. A video teleconsultation is scheduled to discuss findings, explain the treatment roadmap, and obtain informed consent for the workup.

PHASE 2 — Arrival & Comprehensive Diagnostic Workup (DAYS 1–5 IN COUNTRY):